Major pharmaceutical companies have invested immense resources into developing innovative treatments for cancer. Since 1997 the list of the best selling oncology drugs has evolved significantly.
The high pace in drug development is set to continue and in 2017 the whole oncology pipeline has over 600 molecules in late development stage.
style="display:block"
data-ad-format="autorelaxed"
data-ad-client="ca-pub-6652631670584205"
data-ad-slot="7514086806">
Other Oncology Drugs Trends in Last 20 Years:
Luca Dezzani is a Novartis employee. All the views, analysis, and perspectives are fully independent and belongs to the author only. They do not represent the views or opinions of Novartis or any other company or organization. IgeaHub is a pharmaceutical blog created and curated by Luca Dezzani. IgeaHub does not receive any funding or support from Novartis or any other pharmaceutical company.
Comentários